Iovance Biotherapeutics, Inc. (IOVA) Financials
IOVA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 780.4 million | 195.7 million |
2023-09-30 | 852.3 million | 178.3 million |
2023-06-30 | 757.3 million | 178.7 million |
2023-03-31 | 824.8 million | 157.9 million |
IOVA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -87.5 million | 14.4 million |
2023-09-30 | -87.7 million | 15.8 million |
2023-06-30 | -103.5 million | 16.7 million |
2023-03-31 | -105.5 million | 15.7 million |
IOVA Net Income
No data available :(
IOVA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 279.9 million | - | 74.9 million |
2023-09-30 | 361.4 million | - | 78.5 million |
2023-06-30 | 250.9 million | 1.0 million | 79.7 million |
2023-03-31 | 626.3 million | 1.0 million | 82.2 million |
IOVA Shares Outstanding
IOVA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 3.5 million | 87.5 million | 29.9 million | - |
2023-09-30 | 3.6 million | 87.5 million | 27.0 million | - |
2023-06-30 | 9.5 million | 86.3 million | 21.9 million | - |
2023-03-31 | 5.7 million | 82.7 million | 28.1 million | - |
IOVA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 482000 | 14.1 million |
2023-09-30 | 469000 | 4.3 million |
2023-06-30 | 238000 | 2.1 million |
2023-03-31 | - | 5.7 million |
IOVA
Price: $12.88
52 week price:
Earnings Per Share: -1.89 USD
P/E Ratio: -3.92
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 3.5 million
Ebitda: -22.1 millionMarket Capitalization: 3.8 billion